Navigation Links
Comprehensive Review on Sulfonylureas in the Latest Issue of Diabetic Hypoglycemia (05 June 2009)
Date:6/4/2009

LONDON, June 4 /PRNewswire/ -- The latest issue of the online journal Diabetic Hypoglycemia (http://www.hypodiab.com) features an authoritative review on sulfonylureas by Professor Ian Campbell, a leading expert in oral hypoglycemia therapy.

Professor Campbell's review focuses on sulfonylurea-induced hypoglycemia (SIH), which is a well-recognized side-effect of this class of therapy for type 2 diabetes. In the review he discusses the incidence of SIH, with particular reference to the different sulfonylureas. He also reflects on the morbidity and mortality seen with SIH, precipitating risk factors, treatment of SIH, and education of patients and medical staff in the prevention of SIH.

This issue of Diabetic Hypoglycemia also includes a case study on recurring hypoglycemia associated with glibenclamide, by Professor Campbell.

Dr Rory McCrimmon of the Editorial Board reviews the literature on blood glucose monitoring in hypoglycemia, in an editorial entitled 'What we're learning from continuous glucose monitoring.'

This issue of Diabetic Hypoglycemia also features an 'In profile' interview with Professor Stephanie Amiel, a leading expert in the use of neuroimaging in diabetes and hypoglycemia.

About the Journal

Diabetic Hypoglycemia is an influential online diabetes journal. The Editorial Board of hypoglycemia experts peer review all Journal content. The Board is led by Editor-in-Chief Professor Brian Frier (Edinburgh, UK), with Associate Editors: Professor Simon Heller (Sheffield, UK), Professor Christopher Ryan (Pittsburgh, USA) and Dr Rory McCrimmon (Yale, USA). Diabetic Hypoglycemia is published three times a year, providing an interactive forum for readers to share practical knowledge and opinions on the rapidly evolving field of hypoglycemia.

To explore the Diabetic Hypoglycemia website and its key features, our guided tour can be activated by clicking the following link: http://www.hypodiab.com/Teaser/hypodiab.html.

Diabetic Hypoglycemia is published by ESP Bioscience. Support for the journal is provided by an unrestricted educational grant from Novo Nordisk A/S (Bagsvaerd, Denmark).

About ESP Bioscience

ESP Bioscience (a division of ESP Limited, Sandhurst UK) is a publisher of novel medical information products and creates online medical communities. Working in association with its academic partners in the global healthcare community, ESP Bioscience publishes journals, books and online resources.

    Contact:

    Rebecca Drake, Editorial Manager
    E: enquiries@hypodiab.com
    T: +44(0)1344-762531
    F: +44(0)203-0514753



'/>"/>
SOURCE ESP BioScience Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Exceptional Childrens Foundation Merger with Kayne Eras Center Creates One of States Most Comprehensive Nonprofits Serving the Disabled
2. Health and Business Groups Launch Ad Campaign About Need for Comprehensive Smoke-Free Law in Pennsylvania
3. MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers
4. Most comprehensive study of mercury in dental fillings begins
5. Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities
6. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
7. USC receives $7.5M for Comprehensive Center of Excellence in Minority Health
8. LTC Financial Partners (LTCFP) Engages CareScout to Bring Comprehensive Long Term Care Solutions to LTCFP Clients; A One-Stop Shop for All Care Information - An Industry First
9. Health Insurance Finders Debuts A Comprehensive Guide to Family Health Insurance
10. Report: Medicare-Administered Drug Benefit Would be More Affordable, Comprehensive, Stable than Current Private Insurance-Run Drug Benefit
11. NIAID funds $51M contract to create comprehensive model of immune responses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that ... 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the ...
(Date:3/24/2017)... ... ... “End Time GPS”: a dauntless and enlightened study of the second-coming of Christ, ... of published author, Wesley Gerboth, a World War II veteran, with a highly-regarded reputation ... age ninety-one, he shares the Wisdom God bestowed upon him in this publication. ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization ... could be four million Zika-related cases in the Americas within the next year. Lyme ... cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Road in Building 2. The clinic is the group’s second in New Braunfels and ... the company’s second New Braunfels location brings things full circle for the group, “It’s ...
(Date:3/23/2017)... ... March 23, 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria ... teeth the minimum two times a day that dentists recommend. The ramifications of improper oral ... of school and adults missing 164 million hours of work each year due to dental ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017 Research and Markets has ... U.S.: Consumer Strategies" report to their offering. ... Pain Management ... and treat their physical pain, emphasizing consumer survey analysis, including ... sufferers and adults who have selected illnesses/conditions strongly associated with ...
(Date:3/24/2017)... 2017 ShangPharma, a leading life ... drug development and discovery services, technology, and ... announced today the intent for a strategic ... consolidating the Contract Research Organizations (CRO) and ... These entities include ChemPartner Shanghai, ChemPartner Fengxian, ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... to their offering. ... IPF pipeline is very strong with a total of 97 drug candidates. ... and Sanofi are involved in the development of the IPF therapeutics. The ... Phase III stage, 15 are in Phase II stage, 12 are in ...
Breaking Medicine Technology: